Literature DB >> 1985215

Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector.

M Poznansky1, A Lever, L Bergeron, W Haseltine, J Sodroski.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) proviruses containing deletions between nucleotides 301 and 319 express viral proteins but exhibit marked attenuation in the packaging of viral RNA into virions (A. Lever, H. Gottlinger, W. Haseltine, and J. Sodroski, J. Virol. 63:4085-4087, 1989; A. Aldovini and R. A. Young, J. Virol. 64:1920-1926, 1990). Here we report that such packaging-defective proviruses can provide trans-acting viral elements required for the transfer of a HIV-1 vector to Jurkat human lymphocytes. The transferred vector was unable to encode HIV-1 genes, indicating that the long terminal repeats and the immediate flanking viral sequences are sufficient for packaging, reverse transcription, and integration. The generation of replication-competent viruses in this system was reduced to undetectable levels by providing the trans-acting viral functions on two separate expression plasmids. This defective retroviral vector provides a means of efficiently introducing desired genetic elements, in the absence of HIV-1 genes, into HIV-1 target cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985215      PMCID: PMC240552     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Immunologic aspects of the acquired immunodeficiency syndrome and male homosexuality.

Authors:  M S Gottlieb
Journal:  Med Clin North Am       Date:  1986-05       Impact factor: 5.456

2.  A second post-transcriptional trans-activator gene required for HTLV-III replication.

Authors:  J Sodroski; W C Goh; C Rosen; A Dayton; E Terwilliger; W Haseltine
Journal:  Nature       Date:  1986 May 22-28       Impact factor: 49.962

3.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

4.  Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity.

Authors:  J Sodroski; W C Goh; C Rosen; K Campbell; W A Haseltine
Journal:  Nature       Date:  1986 Jul 31-Aug 6       Impact factor: 49.962

5.  Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region.

Authors:  M A Bender; T D Palmer; R E Gelinas; A D Miller
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

7.  Construction and applications of a highly transmissible murine retrovirus shuttle vector.

Authors:  C L Cepko; B E Roberts; R C Mulligan
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

8.  Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells.

Authors:  A Joyner; G Keller; R A Phillips; A Bernstein
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

9.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

10.  Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme.

Authors:  E F Terwilliger; B Godin; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more
  41 in total

1.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 2.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Visualization of transfer of a fluorescently-labeled membrane raft protein to T cells using lentivirus.

Authors:  Jennifer Byrum; William Rodgers
Journal:  Gene Ther Mol Biol       Date:  2005

5.  Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector.

Authors:  T Shimada; H Fujii; H Mitsuya; A W Nienhuis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

Review 6.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

7.  Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.

Authors:  V N Kim; K Mitrophanous; S M Kingsman; A J Kingsman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  The multimerization state of retroviral RNA is modulated by ammonium ions and affects HIV-1 full-length cDNA synthesis in vitro.

Authors:  S Weiss; G Häusl; M Famulok; B König
Journal:  Nucleic Acids Res       Date:  1993-10-25       Impact factor: 16.971

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.